INHIBIKASE THERAPEUTICS INC (IKT) — insider trading
Health Care · NASDAQ
INHIBIKASE THERAPEUTICS INC (IKT) has 11 reported SEC Form 4 insider transactions in our data (latest 2026-06-26).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-26 | Munshi Amit | Director | Grant / award / vesting (derivative) | 155,000 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Aurentz Vincent | Director | Grant / award / vesting (derivative) | 155,000 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Bellini Roberto | Director | Grant / award / vesting (derivative) | 155,000 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Kush Arvind | Director | Grant / award / vesting (derivative) | 155,000 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Canner David | Director | Grant / award / vesting (derivative) | 155,000 | $0.00 | $0 | Form 4 |
| 2026-06-26 | BERMAN DENNIS N | Director | Grant / award / vesting (derivative) | 155,000 | $0.00 | $0 | Form 4 |
| 2026-02-21 | Munshi Amit | Director | Disposition to the issuer | 19,089 | $0.00 | $0 | Form 4 |
| 2026-02-21 | Cabell Christopher | Officer (President & Head of R&D) | Disposition to the issuer | 338,282 | $0.00 | $0 | Form 4 |
| 2026-02-21 | Aurentz Vincent | Director | Disposition to the issuer | 255,299 | $0.00 | $0 | Form 4 |
| 2026-01-05 | Cabell Christopher | Officer (President & Head of R&D) | Grant / award / vesting (derivative) | 900,117 | $0.00 | $0 | Form 4 |
| 2026-01-05 | Iwicki Mark T | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 4,982,706 | $0.00 | $0 | Form 4 |
Ask the chat about IKT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: INHIBIKASE THERAPEUTICS INC (IKT).
Last updated 2026-06-26 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.